Hubei Jumpcan Pharmaceutical (SHA:600566) said China's drug regulator granted Pudilan Xiaoyan oral liquid the status of nationally protected traditional Chinese medicine.
The drug is used to treat upper respiratory infections, according to a Monday filing with the Shanghai bourse.
The protection period is seven years from the announcement date.
Shares of the pharmaceutical company were down 2% in recent trade.